Phase 3 Study Comparing Pomalidomide and Dexamethasone w/Without Daratumumab in Subjects With Relapsed or Refractory MM Who Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.

Trial Profile

Phase 3 Study Comparing Pomalidomide and Dexamethasone w/Without Daratumumab in Subjects With Relapsed or Refractory MM Who Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms APOLLO
  • Most Recent Events

    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 28 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 27 May 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top